lncRNA CASC2与肿瘤化疗耐药实验研究进展

doi:10.11904/j.issn.1002-3070.2024.01.011

Abstract

Abstract: Malignant tumors have become the main cause of human death.With the prolonged use of chemotherapeutic drugs during the treatment process,tumor cell resistance is also constantly increasing.long non-coding RNA(lncRNA)is an important member of the non-coding RNA family.Cancer susceptibility candidate 2(CASC2)is a type of long non-coding RNA,high expression of CASC2 can inhibit tumor cell development and reduce drug resistance of tumor cells by promoting apoptosis,regulating signaling pathways,participating in cellular transmission pathways,competitively binding of miRNA,and changing the protein structure or functional status.This article will provide a comprehensive review of the regulatory effects and mechanism of lncRNA CASC2 on chemotherapy resistance in malignant tumors.

Key words: long non-coding RNA, Cancer susceptibility candidate 2, Chemotherapy, Drug resistance, Tumor

CLC Number:

R730.53

SHANG Hongyue, YAO Manman, LU Yueting, WANG Dixian, ZHAO Qian, LIU Tiejun. Research progress of long non-coding RNA CASC2 in tumor chemotherapy resistance[J]. Journal of Practical Oncology, 2024, 38(1): 67-70.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2024.01.011

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2024/V38/I1/67

References

1 Sung H,Ferlay J,Siegel RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249.
2 Hashemi M,Mirzaei S,Zandieh MA,et al.Long non-coding RNAs(lncRNAs)in hepatocellular carcinoma progression:Biological functions and new therapeutic targets[J].Prog Biophys Mol Biol,2023,177:207-228.
3 Zhou J,Song G,Su M,et al.Long noncoding RNA CASC9 promotes pancreatic cancer progression by acting as a ceRNA of miR-497-5p to upregulate expression of CCND1.[J].Environmental Toxicology,2023,38(6):1251-1264.
4 Lu P,Jiang Y,Xia Z.Long noncoding RNA TUG1 decreases bladder cancer chemo-sensitivity toward doxorubicin through elevating KPNA2 expression and activating the PI3K/AKT pathway via adsorbing miR-582-5p[J].Anticancer Drugs,2023,34(1):144-154.
5 杨钊,赵世光.长链非编码RNA CASC2抑制肿瘤发生发展的研究概况[J].实用肿瘤学杂志,2018,32(2):179-183.
6 Bao MH,Wong CC.Hypoxia,metabolic reprogramming,and drug resistance in liver cancer[J].Cells,2021,10(7):1715-1715.
7 栗敏,白桦,肖鹏,等.LncRNA GALNT5 uaRNA在TRAIL诱导的肺癌A549和HCC827细胞耐药中的作用[J].郑州大学学报(医学版),2022,57(6):745-751.
8 Jin X,Cai L,Wang C,et al.CASC2/miR-24/miR-221 modulates the TRAIL resistance of hepatocellular carcinoma cell through caspase-8/caspase-3[J].Cell Death Dis,2018,9(3):318.
9 Liu Z,Dang C,Xing E,et al.Overexpression of CASC2 improves cisplatin sensitivity in hepatocellular carcinoma through sponging miR-222[J].DNA Cell Biol,2019,38(11):1366-1373.
10 Sun J,Xu H,Lei Z,et al.The lncRNA CASC2 modulates hepatocellular carcinoma cell sensitivity and resistance to TRAIL through apoptotic and non-apoptotic signaling[J].Front Oncol,2021,11:726622.
11 Chen NP,Sun Z,Fässler R.The Kank family proteins in adhesion dynamics[J].Curr Opin Cell Biol,2018,54:130-136.
12 Wang J,Jia J,Zhou L.Long non-coding RNA CASC2 enhances cisplatin sensitivity in oral squamous cell cancer cells by the miR-31-5p/KANK1 axis[J].Neoplasma,2020,67(6):1279-1292.
13 Yang M,Luo Q,Chen X,et al.Bitter melon derived extracellular vesicles enhance the therapeutic effects and reduce the drug resistance of 5-fluorouracil on oral squamous cell carcinoma[J].J Nanobiotechnology,2021,19(1):259-259.
14 Pan L,Chen H,Bai Y,et al.Long non-coding RNA CASC2 serves as a ceRNA of microRNA-21 to promote PDCD4 expression in oral squamous cell carcinoma[J].Onco Targets Ther,2019,12:3377-3385.
15 Li Y,Lv S,Ning H,et al.Down-regulation of CASC2 contributes to cisplatin resistance in gastric cancer by sponging miR-19a[J].Biomed Pharmacother,2018,108:1775-1782.
16 Yang SM,Huang C,Li XF,et al.miR-21 confers cisplatin resistance in gastric cancer cells by regulating PTEN[J].Toxicology,2013,306:162-168.
17 Sun K,Zhang G.Long noncoding RNA CASC2 suppresses esophageal squamous cell carcinoma progression by increasing SOCS1 expression[J].Cell Bioscience,2019,9(1):90.
18 Ying J,Qiu X,Lu Y,et al.SOCS1 and its potential clinical role in tumor[J].Pathol Oncol Res.,2019,25(4):1295-1301.
19 Feng Y,Zou W,Hu C,et al.Modulation of CASC2/miR-21/PTEN pathway sensitizes cervical cancer to cisplatin[J].Arch Biochem Biophys,2017,623:20-30.
20 伍玲,杨勇波.LncRNA CASC2、miR-155-5p与上皮性卵巢癌病人化疗敏感性及预后的相关性研究[J].蚌埠医学院学报,2023,48(2):217-221.
21 Tao L,Tian P,Yang L,et al.LncRNA CASC2 enhances 131I sensitivity in papillary thyroid cancer by sponging miR-155[J].Biomed Res Int,2020,2020:7183629.
22 Gao W,Lin S,Cheng C,et al.Long non-coding RNA CASC2 regulates Sprouty2 via functioning as a competing endogenous RNA for miR-183 to modulate the sensitivity of prostate cancer cells to docetaxel[J].Arch Biochem Biophys,2019,665:69-78.
23 Samadaian N,Salehipour P,Ayati M,et al.A potential clinical significance of DAB2IP and SPRY2 transcript variants in prostate cancer.[J].Pathol Res Pract,2018,214(12):2018-2024.
24 Chiarini F,Evangelisti C,McCubrey JA,et al.Current treatment strategies for inhibiting mTOR in cancer[J].Trends Pharmacol Sci,2015,36(2):124-135.
25 Jiang C,Shen F,Du J,et al.Upregulation of CASC2 sensitized glioma to temozolomide cytotoxicity through autophagy inhibition by sponging miR-193a-5p and regulating mTOR expression[J].Biomed Pharmacother,2018,97:844-850.
26 Tan WL,Jain A,Takano A,et al.Novel therapeutic targets on the horizon for lung cancer[J].Lancet Oncol,2016,17(8):347-362.
27 Xiao XH,He SY.ELF1 activated long non-coding RNA CASC2 inhibits cisplatin resistance of non-small cell lung cancer via the miR-18a/IRF-2 signaling pathway[J].Eur Rev Med Pharmacol Sci,2020,24(6):3130-3142.
28 Zhang X,Dong N,Hu X.Wnt/β-catenin signaling inhibitors[J].Curr Top Med Chem,2023,23(10):880-896
29 刘红文,王贞,张启慧,等.lncRNA CASC2C靶向Wnt/β-catenin信号通路影响口腔鳞癌顺铂敏感性的实验研究[J].临床肿瘤学杂志,2020,25(10):876-881.
30 Al-Zahrani MH,Assidi M,Pushparaj PN,et al.Expression pattern,prognostic value and potential microRNA silencing of FZD8 in breast cancer[J].Oncol Lett,2023,26(5):477-477.
31 Majidinia M,Yousefi B.Long non-coding RNAs in cancer drug resistance development[J].DNA Repair(Amst),2016,45:25-33.

[1]	ZHONG Nvjuan, MA Jingyu, XU Zhida. The incidence and mortality of malignant tumors in Fuqing city,Fujian province in 2019 and trend analysis from 2015 to 2019 [J]. Journal of Practical Oncology, 2024, 38(1): 1-6.
[2]	BO Yun, HANG Wenlu, ZUO Shurun, Dong Yuan, LI Haiquan. Effects of long non-coding RNA OTUD6B-AS1 on proliferation,invasion and migration of lung adenocarcinoma A549 cells [J]. Journal of Practical Oncology, 2024, 38(1): 13-17.
[3]	ZHENG Pengfei, DONG Liangpeng, GAO Yanxin, ZHANG Yifu, QIN Shuang. Effect of interleukin-38 to CD8⁺T lymphocyte function in patients with breast cancer [J]. Journal of Practical Oncology, 2024, 38(1): 30-36.
[4]	XIE Junling. Research progress of activated leukocyte adhesion molecule in breast cancer [J]. Journal of Practical Oncology, 2024, 38(1): 45-49.
[5]	GAO Yuan, TANG Yuhan, WANG Lu, ZHAO Wenhui. Research progress of cuprotosis in tumors [J]. Journal of Practical Oncology, 2024, 38(1): 50-54.
[6]	XIAO Ding, BAI Juncheng, ZHANG Bin. Research progress of signal pathways related to the anti-tumor effect of Astragalin [J]. Journal of Practical Oncology, 2024, 38(1): 62-66.
[7]	WU Chunlong, SUN Weiling. Analysis of age-period-cohort model for incidence and mortality of digestive tract tumors in China [J]. Journal of Practical Oncology, 2023, 37(6): 459-465.
[8]	CAO Xinyu, ZHOU Xu, WANG Quan, JIANG Wei. Potential mechanisms and prediction methods of anticancer drug resistance [J]. Journal of Practical Oncology, 2023, 37(6): 491-495.
[9]	CHENG Jin, WANG Wei. Research progress on retinoic acid-induced proteins in malignant tumors of the digestive system [J]. Journal of Practical Oncology, 2023, 37(6): 502-506.
[10]	ZHAO Shibo, CHEN Yongfeng, LI Huiyi, FU Aizhen. Research status of Agrin involvement in the occurrence and development of malignant tumors [J]. Journal of Practical Oncology, 2023, 37(6): 507-512.
[11]	SONG Shuming, LI Gaiqin, ZHANG Lifeng, XU Kai, MAO Wenjing, ZHANG Guanghui. Epidemiological analysis of inpatients with malignant tumor at the Affiliated Tumor Hospital of Xinjiang Medical University from 2010 to 2020 [J]. Journal of Practical Oncology, 2023, 37(5): 389-394.
[12]	XUE Liangfang, WANG Xinshu, ZHANG Yunyan, CHENG Haiyan, JIN Hong, WANG Yaoxian, YANG Shanshan, LI Qi. A comparative study on the efficacy and adverse reactions of nituzumab and bevacizumab combined with synchronous radiotherapy and chemotherapy in the treatment of locally advanced cervical cancer [J]. Journal of Practical Oncology, 2023, 37(5): 416-421.
[13]	LIU Yuanlin, FENG Li. Research progress in the mechanism of miR-192-5p in malignant tumors [J]. Journal of Practical Oncology, 2023, 37(5): 439-442.
[14]	LUO Tingfan, SUN Pengfei. Research progress of macrophages/microglia in the microenvironment of glioma [J]. Journal of Practical Oncology, 2023, 37(5): 443-448.
[15]	WANG Xinping, ZHANG Ziyun, WANG Xuedong. Research progress on the roles of non-coding RNA in chemotherapy resistance of breast cancer [J]. Journal of Practical Oncology, 2023, 37(5): 454-458.

Research progress of long non-coding RNA CASC2 in tumor chemotherapy resistance

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments